Trial Profile
Phase II study of fixed dose rate Gemcitabine-Oxaliplatin Integrated with concomitant 5FU and 3-D Conformal Radiotherapy for the treatment of localised pancreatic cancer: GOFURTGO.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GOFURTGO
- 15 Dec 2010 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 29 Dec 2009 New trial record